The Israel Institute of Biological Research, which is developing an Israeli COVID vaccine that was successful in the first stage of clinical trials, will not be conducted the critical third stage of clinical trials – in which the vaccine is tested on some 30,000 volunteers and ultimately determines whether or not it is effective – in Israel.
The fact that Israel has already launched a campaign to vaccinate the public using vaccines from Pfizer and Moderna could interfere with the IIBR's ability to continue its clinical trials in Israel.
Follow Israel Hayom on Facebook and Twitter
"In this situation, it appears they [the IIBR] won't be able to conduct Stage III trials in Israel," virologist Professor Amos Panet of the Hebrew University of Jerusalem, a member of the committee overseeing the development of the IIBR vaccine, told Israel Hayom.
